1

Diabetes

and Oncology IR Thematic

Seminar

September

30, 2010

Forward Looking Statements

This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts.

These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects,”

“anticipates,”

“believes,”

“intends,”

“estimates,”

“plans”

and similar expressions.

Although sanofi-aventis’

management believes that the expectations reflected in such forward-

looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling

and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities as well as those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under “Risk Factors”

and “Cautionary Statement Regarding Forward-Looking Statements”

in sanofi-aventis’

annual report on Form 20-F for the year ended December 31, 2009.Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

2

3

Introduction

Christopher A. ViehbacherChief Executive Officer

4

Agenda

Overview of Oncology Business Division and Next

Wave

of Oncology

DrugsDebasish Roychowdhury, Senior Vice President - Oncology Division

Update on BiPar

and IniparibAtul Dhir, CEO - BiPar Sciences

Beyond Iniparib: Additional Phase III Candidates and Early Clinical Stage Pipeline

Tal Zaks, Vice President, Head of Development - Oncology Division

Concluding RemarksDebasish Roychowdhury, Senior Vice President - Oncology Division

Q&A Session

Sanofi-aventis Poised for Growth in Diabetes

Pierre Chancel, Senior Vice President - Diabetes Division

Building up on a Strong Commercial Presence

Christoph Heinemann, Vice President, Strategy & Operations - Diabetes Division

Today’s Commitments for the Treatments of Tomorrow

Jochen Maas, Vice President, Research & Development - Diabetes Division

Concluding RemarksPierre Chancel, Senior Vice President - Diabetes Division

Q&A Session

Oncology Diabetes

5

Oncology IR Thematic

Seminar

September

30, 2010

6

Overview of Oncology Business Division and Next

Wave

of

Oncology

Drugs

Debasish

RoychowdhurySenior Vice President – Oncology Division

7

Oncology – A Strategic Priority

Unmet

Medical

Need

Impact on Society

Innovative

Science

Strong

Heritage

Cancer is a leading cause of death globally(1) requiring new treatment options

(

1

)

Source: World Health Organization; cancer accounted for 7.9 million deaths in 2007(

2

)

Source: The American Cancer Society and Livestrong

report “The Global Economic Cost of Cancer”

Cancer is the #1 reason for economic loss among the top causes of death(2)

Sanofi-aventis is

poised

to maximize

the opportunity

and potential

in oncology

Taxotere®

and Eloxatin®

are the foundation

of chemotherapy

Tumors

now

characterized

at

the molecular

level, treatments

more personalized

8

Our Strategy

in Oncology

is

Based

on Five Core

Beliefs

Innovative

treatments

-

Proven

substantial

benefits

are necessary

Personalization

-

Biomarkers, patient stratification tools, and targeted

therapies

Environment

shaping

-

Facilitating

patient access

to medicine

Creation

of more synergies

-

Integrate

business functions

into

the Division

External

partnering

-

Embrace

external

innovation to leverage

internal

capabilities

Vitry, France headquartersCambridge, MA headquarters

9

A New Approach to Developing Cancer Therapies

Innovative targets

From To

Our Oncology

Division is

flexible in adapting

to a fast

changing

environment

Known

targets

Small molecules

Best in class, differentiation classical

Common cancers, all comers

Monotherapy, add-on

Minimal biomarkers, diagnostics, imaging

Internal discovery

U.S. and EU centric

Small molecules, biopharmaceuticals, nanodelivery

technologies, etc.

First in class, best in class, differentiated by superior efficacy and unmet need

Genetically stratified, smaller populations

Combination therapies, factorial designs

Translational medicine embedded trials

Externalization

Increased focus on Asia

10

Redefining

our

Oncology

Presence

Creating

an empowered

and agile Oncology

Division

More than 100 new hires

to the oncology division in 2010 Many key hires have academia and biotech backgrounds Oncology Division will also be based in Cambridge

to benefit from networking with a leading scientific community

R&D centers reduced from 11 to 3

Jevtana®

NDA filed in about

4 months

of pivotal results versus the industry average of 6 to 8 monthsImproved target selection and the use of translational medicine to reduce development costs

Creation of a new Oncology Review Board to optimize and prioritize

oncology investmentsGlobal Protocol Review Committee established to facilitate accelerated filing timelinesEmpowerment

of teams

Streamlining GovernanceRecruiting

Talent

11

Maximizing

Value Through

the Integration

of R&D and Commercial Activities

Fully integrated in 9 key countries

Sales & Marketing, R&D, Market Access, Medical affairsImproves speed to marketFacilitates collaborative decision makingRest of world managed through regional offices

Creation of a biotech center of excellence in ChinaResearch and development centers

Cambridge, MAVitry, FranceSan Francisco, CA (BiPar)

Oncology

Division Direct countries in

Oncology

Divisionfacilities

U.S.

Russia

ChinaJapan

France

Germany

Italy

Spain

UK

12

New Leadership Team Broad, Diverse and In-Depth Expertise

Alain Curaudeau

VP, Head of Strategy & Portfolio Management, Oncology

•

SVP, Project Planning & Management at

QTL•

Head of Project Management, Aventis

Christoph

Lengauer

VP & Head of Oncology Drug Discovery & Preclinical Research

•

Exec Dir & Sr

Unit Head Oncology Discovery, Novartis Institute for Biomedical Research

•

Adjunct

Associate

Professor of

Oncology, Johns

Hopkins

University

Tal Zaks

VP, Head of Development, Oncology

•

Genetic Research Group, Head Oncology Clinical Research Team, Cephalon

•

Adjunct Associate Professor of Medicine, University of Pennsylvania

Tamas Suto

VP & Head of Medical Affairs, Oncology

•

Therapeutic

Head for Haematology/Oncology

& Head of International Medical

Affairs, Amgen

Debasish

Roychowdhury

SVP & Head of Oncology Division

•

Drug development

and clinical

development

in oncology

& hematology

at

GSK and Lilly

•

Oncologist, hematologist

John Harrington

VP & Chief Commercial Officer, Oncology

•

VP & Head US Oncology

Division, sanofi-aventis

•

VP Metabolism

Business Unit, sanofi-aventis US

•

VP Primary

Care Sales, Aventis US

Atul

Dhir

CEO, BiPar Sciences

•

President, Cancer Research

Group, US Oncology

•

VP Healthcare, Monsanto •

Consultant, McKinsey

13

BiPar

internal

project

externalized

project

External projects to have the choice of using sanofi-aventis platforms or working directly with external partners

Overall objective is to have at least 50% of projects externalized

Bring in learnings

and transform internal process

Competitive funding process for internal and external projects

PI3K

Internal

and External

Expertise as well

as Networks to be

Maximized

14

A Partner of Choice

in Oncology

Demonstrating

our

ability

to add

valueCutting-edge

technical

expertiseInvestigating

novel-novel

combinationsGlobal execution

and distribution, especially

in Emerging

MarketsProviding

access

to a broad

industrial platform

and control over supply

chain

Allowing

partner

to develop

and prosperEnabling

partner

to lead

key

activitiesCollaborating

while

partner

develops and expands

expertiseFlexible deal structure

Regeneron

-

-

Exclusive option of co-development-

Opportunity

for partner

to lead

clinical

development-

Acquisition but with

significant

autonomy

15

Emerging

Markets

–

Executing

a Local Approach

CHINA ESTIMATED CANCER INCIDENCE: BOTH SEXES, ALL AGES

185

221

259

402

464

522

0 100 200 300 400 500

Breast

Colorectum

Oesophagus

Liver

Stomach

Lung

Thousands

Addressing regional differences in cancer epidemiology and biology

Eloxatin®: Development of liver cancer indication for the Asia-Pacific regionJevtana®: Asia-Pacific region to lead development in gastric cancer

Creating basic research

alliances regionally, especially North East Asia Specific development

plans for

these regions -

executed in parallelSynchronized submission

timelines

Providing access through multi-tiered pricing

strategies or

risk sharing models

Differences

in incidence require

regional

approach

to each

indication

China Estimated

Cancer Incidence(1)

Number

of new patients (2008)

(1) Source: GLOBOCAN 2008, IARC -

12.6.2010

16

Maximizing

the Emerging

Markets

Opportunity

(

1

)

Pricing

comparisons

are adjusted

to a baseline

of 100.(

2

)

HRPC: Hormone Resistant

Prostate Cancer

Sustainable

global sales post EU/U.S. patent expiries

expected

to be

around

€500m

New indications in ChinaHRPC(2) in 2010Advanced gastric

cancer in 2012Head and neck cancer in 2014

Expand

the gastric

cancer indication in other

Emerging

MarketsPursue

breast

and prostate cancer

indications in India, Russia, and Brazil

0

50

100

150

200

EU5 China Russia Brazil

Taxotere®

Relative Pricing(1)

17

Leveraging

Brand Equity

Settlement of U.S. patent litigation Inventory workdown

is progressingReimbursement for Eloxatin®

expected to return

to

levels

seen prior

to generic entry in early 2011

Planned growth drivers in China:Advanced HCC(1)

in 2011Liquid solution launch in 2012Advanced Gastric cancer in 2014Adjuvant Gastric cancer in 2015

Sustainable

global sales post EU/U.S. patent expiries

expected

to be

around

€300m

Generic

oxaliplatin

Branded

Eloxatin

U.S. Eloxatin® Demand (MGs in 000s)(2)

-

300

600

900

1,200

1,500

Jan-10 Feb-10 Mar-10 Apr-10 May-10 Jun-10 Jul-10

(

1

)

HCC: Hepatocellular

cancer(2)

Source: IMS

U.S. Eloxatin®

Demand (MGs

in 000s)(2)

18

Pipeline Rebuild

Underway…February

2009 Before Portfolio Review

Aflibercept

Phase I Phase II Phase III Marketed

larotaxel

Taxane

–

Tubulin

inhibitor

Pancreatic, Bladder cancer

xaliproden

Neurotrophic

peripheral sensory neuropathies

AVE 1642 IGF1R mAb

Breast Cancer

alvocidib

Cyclin-dependent kinase

inhibitor

CLL

ombrabulin

Vascular disrupting agent

Sarcoma

Jevtana®

Taxane

-

Tubulin

inhibitor

Prostate cancer

aflibercept

1L mProstate; 2L NSCLC;

2L mCRC;

Oforta®

fludarabine

phosphate

Elitek®

rasburicase

Eloxatin®

oxaliplatin

Taxotere®

docetaxel

Project terminated

(Feb

2009 to Sept 2010)

SAR3419 Maytansin-loaded anti-CD19 mAb

non-Hodgkin’s lymphoma

SSR97225 Antimitotic

agent

TroVax

(SAR109659)

Renal Cancer

aflibercept

1st line mPancreatic

cancer

19

Pipeline Rebuild

Underway…September

2010 Rich and Strong Portfolio

iniparib

PARP inhibition

mTNBC; NSCLC

SAR3419*

Maytansin-loaded anti-CD19 mAb

non-Hodgkin’s lymphoma

SAR245408 (XL147)

Oral PI3K inhibitor

Endometrial

& breast

cancer

Aflibercept

Taxotere®

docetaxel

SAR650984* Anti-CD38 naked mAb

Hematological malignancies

SAR103168

Multikinase

inhibitor

AML

Elitek®

rasburicase

Oforta®

Fludarabine

phosphate

ombrabulin

Vascular disrupting agent

Sarcoma

SAR256212 (MM121)

anti-ErbB3 mAb

Breast cancer

SAR302503 JAK2 inhibitor Myelofibrosis

SAR153192* Anti-DLL4 mAb

Solid tumors

iniparib

PARP inhibition

Ovarian

cancer

aflibercept* VEGF-Trap

1st

line colorectal cancer

Phase I Phase II Phase III Marketed

SAR566658*

DS6 Antibody-Drug Conjugate

DS6 Positive Solid

Tumors

aflibercept* 1st line mProstate;

2nd line NSCLC; 2nd line mCRC

Jevtana®

cabazitaxel

Eloxatin®

oxaliplatin

SAR245409

(XL765)

Oral dual inhibitor

of PI3K/mTOR

Cancer

New clinical

project

since

February

2009

* Biologic

product

20

Our Next

Wave

of Oncology

Drugs Maximizing

Late

Stage Opportunities

Iniparib

Aflibercept Ombrabulin

21

New semi-synthetic taxaneSelected to overcome the emergence of taxane

resistance(1)

Mechanism of actionMicrotubule stabilizer(2)

Estimated new cases of prostate cancer in U.S. in 2009 =192,000;

Deaths 27,360

575,000 new cases of Prostate Cancer diagnosed in Europe and U.S. yearly(3)

mHRPC

accounts for 15% of patients

Taxotere®

chemotherapy is the current standard of care in mHRPC

After Taxotere®

failure, Jevtana®

is the only approved drug -

supportive care, unapproved agents, or hospice are other treatment options

No improvement in overall survival demonstrated with current therapies

A New Cytotoxic

Agent

Prostate cancer

The molecule

(

1

)

Attard

G, Greystoke

A, Kaye S, De Bono J. Pathol

Biol

(Paris). 2006;54(2):72-84.(

2

)

Pivot X, Koralewski, P, Hidalho

JL, et al. Ann Oncol. 2008;19(9):1547-1552.(3) Ferley

J et al. Eur

J Cancer 2010 –

American Cancer Society, Facts & Figures, 2009

22

0

20

40

80

60

100

0 month 6 months 12 months 18 months 24 months 30 months

cabazitaxel+prednisone

(CBZP)

mitoxantrone+prednisone

(MP)

mitoxantrone

+ prednisone 377 300 188 67 11 1

cabazitaxel

+ prednisone 378 321 231 90 28 4

Number

at

risk

Proportion

of Overall

Survival

(%)MP CBZP

Median

OS (months) 12.7 15.1

Hazard

Ratio 0.70

95% CI 0.59–0.83

P-value <.0001

Source: TROPIC data per the Jevtana

product insert

Overall

Survival

(ITT Analysis) from

TROPIC

23

MP (n=371) CBZP (n=371)

All grades (%) Grade ≥3 (%) All grades (%) Grade ≥3 (%)

Any

adverse event 88.4 39.4 95.7 57.4

Febrile

neutropenia 1.3 1.3 7.5 7.5

Diarrhea 10.5 0.3 46.6 6.2

Fatigue 27.5 3 36.7 4.9

Asthenia 12.4 2.4 20.5 4.6

Back pain 12.1 3 16.2 3.8

Nausea 22.9 0.3 34.2 1.9

Vomiting 10.2 0 22.6 1.9

Hematuria 3.8 0.5 16.7 1.9

Abdominal pain 3.5 0 11.6 1.9

Most Frequent

Treatment-Emergent AEs in ≥2% of Patients (Grade ≥3)(1): Safety

Population

(1) Sorted

by decreasing

frequency

of events

grade ≥3 in the CBZP arm.2010 Genitourinary

Cancers SymposiumProgress in Multidisciplinary

Management

24

Jevtana Abraxane Afinitor Ixempra Sprycel Tasigna

Launch

Exceeding

Expectations

Launch

Analogs

(Sales: 2-months

post launch)(4)

(1) Factors

in analog

selection

include

2L or 3L indication in smaller

metastatic

patient populations with

unmet

medical

need(2) National Comprehensive

Cancer Network(3) EUA: European

Urology

Association(4) Source: IMS NSP

Sales tracking ahead of other analogs(1)

at a similar time post-launchFY 2010 sales expected to be around €60m

Reimbursement:80% of Medicare carriers have made coverage decisionsMinimal formulary restrictions by the vast majority of payorsMajority of plan decisions are expected by early 2011

Adopted into the NCCN(2)

and EUA(3)

guidelinesSafety profile since launch has been consistent with the TROPIC trial

® ® ® ® ®

25

Global Rollout

Beginning

in 2011

EuropeCHMP opinion expected

in H1 2011380,000 new cases of prostate cancer annually12% mortality

rateAbout 25,000 to 30,000 cases are treated

with

chemotherapy

Emerging

Markets2011: Brazil, South Korea

planned

launches2012: Turkey, South Africa

planned

launchesRussia

filing

submitted

in Q3 2010

2010 2011 2012

Planned

launch

schedule*

* non exhaustive

26

New Indications to Drive Future Growth

Probability

of Success

Fast

erLa

unch

Tim

ing

Weaker

Slow

er

Stronger

Asymptomatic

prostate cancer

2L mHRPC

2L SCLCGastric

1L mHRPC

Size of circle represents relative patient population size Based on total U.S. incidence of cancer type (not specific patient segment)(1) Cabazitaxel

doses of 25 mg/m²

or 20 mg/m²

will be studied

Phase III study in first line prostate cancer to begin enrolling Q1 2011

Study to include about 1,100 mHRPC

patients

Primary endpoint: superiority of cabazitaxel(1)

vs. docetaxel

in OS

Phase II second line small cell lung cancer study to begin H2 2011

Early clinical work in asymptomatic prostate cancer to begin in 2011

Phase I bridging study in Japan to begin Q4 2010

Jevtana®

global peak sales in 2L mHRPC

expected to be in the range of €300m to €500m

Jevtana®

Development

Opportunities

BiPar is a wholly owned subsidiary of sanofi-aventis 27

Update on BiPar

& Iniparib*

Atul

Dhir, CEO –

BiPar

Sciences

*Iniparib

is

the United States Adopted

Name (USAN) for the investigational

PARP1 inhibitor, BSI-201

BiPar is a wholly owned subsidiary of sanofi-aventis 28

The BiPar

Model: A New Model for Drug Development

Large Pharma

Global Scale Technical expertise / Depth

Process Discipline

BiPar

Model

Building an innovative

platform

within

sanofi-aventis to improve

speed and efficiency

in drug

development

Biotech

Entrepreneurial Flexible / Nimble

Outsourced

partners

BiPar is a wholly owned subsidiary of sanofi-aventis 29

Iniparib: A novel

anticancer

agent

PARP: Poly ADP-Ribose Polymerase(1)

Phase 1b ASCO ’08 poster presentation

(2) Phase 1 ASCO ’08 poster presentation (3) Phase 2 mTNBC

SABCS ’09 oral presentation(4) ASCO 2010 online abstract: Pharmacokinetics of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in cerebrospinal fluid (CSF) of a breast cancer patient with

carcinomatous

meningitis. Michael Castro, Lingyun

Li, and Todd Stallings

• Small molecule: penetrates blood

brain

barrier(4)

• Novel

agent for treating tumors

with

DNA repair

defects

• Expected

to be

combined safely

with

multiple

chemotherapy

agents(1)

• Clinical

evidence

for efficacy in advanced

breast

cancer

• No significant

side

effects

at recommended

dosing(1,2,3)

Chemotherapy

Plus Iniparib

DNA Not

Repaired

Chemotherapy

Chemotherapy

Alone

PARP1 Facilitates

DNA Repair DNA Repair

PARP1 Activity

InhibitedIniparib

Hypothesized

Anti-Tumor

Activity

Tumor

DNA Damage

BiPar is a wholly owned subsidiary of sanofi-aventis 30

Iniparib

in mTNBC: Phase II Trial Interim Data (Overall Survival)

O'Shaughnessy

J, et al. SABCS 2009. Abstract 3122. Months

OS,

%

BiPar is a wholly owned subsidiary of sanofi-aventis 31

Rapid Progress in Development of iniparib

in mTNBC

• Phase II study in mTNBC• Overall Survival advantage without added toxicity• Final results in ESMO (October 2010)

• Phase III in mTNBC• Completed enrollment in February 2010• Regulatory submission planned for Q1 2011 in U.S.

and Q2 2011 in EU• Clinical development in mTNBC

started in Japan

• New trials to explore new combinations, schedules, etc. started in mTNBC

• Neoadjuvant

trials initiated in the U.S. and EU and to lay the groundwork for adjuvant therapy in early TNBC

TNBC: 15%

Breast

Cancer

U.S. ~14,000EU: ~ 17,000First, second & third line(4)

References:(1) Carey L et al. JAMA. 2006;295:2492-2502.

(2) Swain S. ASCO Annual Meeting. June 3, 2008.

(3) Public epidemiology sources and company models (4) Public epidemiology sources and company models

mTNBC

Population

BiPar is a wholly owned subsidiary of sanofi-aventis 32

Lifecycle

Plan for iniparib

Broad development

plan in multiple cancer indications

First WaveLead

Indication

Bladder

CancerPancreatic

CancerColorectal Cancer

Small Cell

Lung Cancer Head and Neck Cancer

Glioblastoma

Multiforme

Second Wave

Squamous

NSCLC

Recurrent Ovarian Cancer

Early-Stage TNBC

HER2-/HR+ Metastatic Breast Cancer

Metastatic Triple Negative Breast Cancer (mTNBC)

BiPar is a wholly owned subsidiary of sanofi-aventis 33

The Squamous

Non-Small Cell Lung Cancer Opportunity

• Squamous

NSCLC biologically an attractive target

• PARP1 upregulation(1)

• Associated with basal-like phenotype, similar to TNBC(2,3)

• Evidence of DNA repair impairment of BRCA pathway

• High frequency of microsatellite instability

• High unmet patient need

• Gemcitabine

+ Carboplatin

commonly used in NSCLC

(1) Ossovskaya

et al. Genes and Cancer, in pressDakir

et al. Carcinogenesis 2008;29:2377

(2) Dakir

et al. Carcinogenesis 2008:29:2377(3) Chu et al. Histopathology 2001;39:9

(3) Reis-Filho

et al. Virchows

Arch 2003;443:122(4) GLOBOCAN 2008 (http://globocan.iarc.fr/)

(5) American Cancer Society: Cancer Facts and Figures 2010. Atlanta, Ga: American Cancer Society, 2010.

NSCLC: 80%

Lung cancer

Squamous

cell: 25-30%

Lung cancer deaths

in the U.S.: 222,520 in 2010(4,5)

BiPar is a wholly owned subsidiary of sanofi-aventis 34

The Development of Iniparib

in Lung Cancer

Phase 3 Squamous

Lung Cancer Study

(International)

Phase 2 Non-Small Cell

Lung Cancer Trial (EU only)

STAGE IV

Squamous

Cell

Lung Cancer

n=825

STAGE IV

Squamous

Cell

Lung Cancer

n=825

GemcitabineCarboplatinGemcitabineCarboplatin

GemcitabineCarboplatin

iniparib

GemcitabineCarboplatin

iniparib

STAGE IV

Non-Small Cell

Lung Cancer

n=105

STAGE IV

Non-Small Cell

Lung Cancer

n=105

GemcitabineCisplatin

GemcitabineCisplatin

GemcitabineCisplatininiparib

GemcitabineCisplatininiparib

2:1

Status

• Initiated

in US in March 2010

• EU and ROW sites opening in Q4 2010

• Primary

analysis: H2 2012

• Initiated

in EU in May 2010

• Close to half

of patients accrued

• Primary

analysis: H2 2011

1:1

BiPar is a wholly owned subsidiary of sanofi-aventis 35

Iniparib

Development

in Recurrent

Ovarian

Cancer

High unmet

need• Leading

cause of death

from

gynecologic malignancy

• Poor

prognosis

in advanced-stage disease

Rationale

and opportunity

for iniparib• Preclinical

activity

of iniparib

in ovarian cancer models(2)

• Sporadic

cancers associated

with BRCA1/2 dysfunction

• PARP1 is

upregulated

in ovarian

cancers(3)

• Gemcitabine/carboplatin

is

established regimen

in recurrent

ovarian

cancer

(1) Jemal

et al. CA Cancer J Clin 2009;59:225.(2) Ossovskaya

et al. AACR 2008(3) Ossovskaya

et al. AACR 2007

Platinum- Sensitive: ~65%

Ovarian cancer

~22K new diagnoses and ~15K deaths

in the U.S. in 20091

BiPar is a wholly owned subsidiary of sanofi-aventis 36

Ongoing

Phase 2 Studies

in Recurrent

Ovarian

Cancer

Phase 2 Platinum-Sensitive Ovarian

Cancer (U.S.)

Platinum-Sensitive Recurrent Ovarian

Cancer

Gem/Carbo

+ iniparib

n=41

Platinum-Sensitive Recurrent Ovarian

Cancer

Gem/Carbo

+ iniparib

n=41

Stage 1(n=17)

Stage 1(n=17)

Status• Initiated

in Dec

2009• Minimum 8 responses

to proceed

to Stage 2• Stage 1 response

threshold

reached• Interim

analysis: H1 2011

Stage 2(n=24)

Stage 2(n=24)

Phase 2 Platinum-Resistant

Ovarian

Cancer (U.S.)

Platinum-Resistant Recurrent Ovarian

Cancer

Gem/Carbo

+ iniparib

n=48

Platinum-Resistant Recurrent Ovarian

Cancer

Gem/Carbo

+ iniparib

n=48

Stage 1(n=23)

Stage 1(n=23)

Stage 2(n=25)

Stage 2(n=25)

• Initiated

in Dec

2009• Minimum 4 responses

to proceed

to Stage 2• Stage 1 response

threshold

reached• Interim

analysis: H1 2011

BiPar is a wholly owned subsidiary of sanofi-aventis 37

Conclusions

• Iniparib

is a leading anti-cancer agent with PARP inhibitory activity with a survival advantage in mTNBC

and an excellent safety profile

• Iniparib

regulatory

submissions

in the U.S. and EU on track

for 2011

• Major progress

has been made in developing

iniparib

in breast, lung

and ovarian

cancer

• Iniparib

has tremendous

potential

across

multiple cancers both clinically

and commercially

38

Beyond iniparib: Additional Phase III Candidates

Early Clinical Stage PipelineTal ZaksVice President, Head of Development

39

Aflibercept and Ombrabulin A Commitment

to Targeting

Tumor

Vasculature

Antiangiogenic

approach:

Prevention of new vessel growthChronic inhibition

of neovascularization

Vascular-disrupting approach:

Tumorinitiation

Late

stageDissemination

Vascularizedtumor

Angiogenicswitch

Avascularphase

Disruption of microvessels

Acute blood flow shutdown, extensive tumor necrosis

aflibercept ombrabulin

40

Aflibercept –

Novel Anti-VEGF Candidate Differentiated from Bevacizumab

Partnered with worldwideVEGF Trap: a fusion protein blocking VEGF, a well-validated anti-angiogenic

approach

Structure of VEGF Trap

Humanized MAb~160,000 MWKd

= 400-1000pMOnly blocks primate VEGF-AForms Immune Complex with VEGF-A

All human amino acid sequences~110,000 MWKd

= 0.5pM (tighter than natural receptors)Blocks all mammalian VEGF-A, as well as VEGF-

B & PIGFBinds VEGF-A as monomer without Immune Complex formation

Bevacizumab Aflibercept

41

Aflibercept –

Development

Program

Three

Phase III studies

fully

enrolledVELOUR study

continues based

on recommendation

by IDMC(1)

(

1

)

IDMC: Independent Data Monitoring Committee. Recommendation

of IDMC was

announced

in September

2010

XL147(PI3K)

Phase III VELOUR

Indication Design # of patientsPhase / Study

Phase III VITAL

Phase III VENICE

2nd

line metastatic non-small cell lung cancer +

Taxotere®

2nd

line metastaticcolorectal cancer

+ FOLFIRI (folinic

acid / 5-FU / irinotecan)

1200

900

1240

Data Expected

Final analysis

H2 2011

Interim

analysis

H1 2011/

Final analysis

H1 2012

Final analysis

H1 2011

1st

line metastatichormone resistantprostate cancer +

Taxotere®

prednisone

Phase II AFFIRM 230 Final Analysis

H2 20111st line metastaticcolorectal cancer

42

Ombrabulin – Most Advanced Vascular Disrupting Agent

Good safety profile and encouraging signs of activity in Phase I/II(3)

No QT prolongation(1)

observed and very limited hematotoxicityAntitumor activity observed in combination with chemotherapy

Complete Response observed in triple-negative breast cancer patient

Antivascular

effect demonstrated using DCE-US(2)

No potential for “VEGF-rebound”

effect

Promising

earlyPhase II data atASCO & ITC 2010

2 classes of Vascular

Disrupting

Agents with

different

molecular

targets

Unidentified target:Vadimezan

(ASA404): Phase III NSCLC 1st

line trial failed

Tubulin-binders:OmbrabulinFosbretabulinPlinabulin

(

1

)

Toxic

effect

on ECG observed

with

some

agents in the class(

2

)

Digital Contrast

Enhanced

Ultrasound(

3

)

Presented

at

ASCO 2010

43

Ombrabulin Development Program

Mechanism

of action and preclinical

data support development

in most

solid tumors

High unmet

medical

need

in soft-tissue sarcoma

after

failure

of standard therapyOrphan

Drug

status

expectedAround

30,000 patients in the U.S. and EU with

soft-tissue sarcoma

Pivotal

Phase III

study

is

more than

85% enrolledOn track

for U.S. and EU filing

in 2011Two

Phase II

proof of concept trials in preparation

1st

line NSCLC

to start

20112nd

line ovarian

cancer

to start

2011

Baseline

After

cisplatin/ombrabulin

Shut Down of Tumor Blood Flow(1)

(1) DCE-Ultrasound

images of an ovarian

cancer patient treated

in a combination

Phase I trial; the red

contour outlines

the tumor

mass.

44

Early

Clinical

Stage Pipeline: Our Oncology Discovery Approach

Discovering

drugs

against common

cancer pathways

Focus on antibody

drug conjugates

Leverage

external complementary

innovation

DrugCancer Target

Pathogenesis1

2

3

45

Biological

Importance of

PI3K Pathway

in Cancer

C2

Tumor Fraction mutatedColon Brain Gastric Breast

1/24 (4%)

74/234 (32%) 4/15 (27%)

3/12 (25%) 1/12 (8%)

Lung

8% 47% 33%

E545K H1047R

(

1

)

Parsons et al., Nature 436 (2005)Diagram

Source: Samuels

et al., Science 304 (2004) , Samuels

et al., Cancer Cell

561 (2005)

PI3K pathway:Mutations that

activate

this

pathway

occur

frequently

in human

tumors

and promote

tumor

cell

growth

and survival(1)

Activation of the pathway

is

associated

with

resistance

to cancer therapiesTwo

drugs

targeting

this

pathway

in clinical

development: XL147, XL765Preclinical

cancer research

projects

against

PI3K alpha and PI3K beta

Tumor Fraction Mutated

Colon

Brain

Gastric

Breast

Lung

32%

27%

25%

8%

4%

Locations of Activating Mutations in the PI3K Gene

46

XL147 -

Potentially

First in Class

As a single-agentStrong inhibition of the PI3K/AKT

pathwayModerate inhibition of the ERK/MAPK pathway(1)

Preliminary anti-tumor activity in NSCLC, adenocarcinoma, vaginal carcinomaPhase II program started

Evaluating combinations with standard of care and novel agents

No apparent additive toxicity or PK interaction Upregulation

of ERBB3 is seen in a cell line model treated with XL147(2)

Maximum tolerated

dose is

600mg(1) Demonstrated

in all tumor

samples

at

the maximum tolerated

dose(2) Hanker, Translational

Cancer Medicine

Meeting, 2010

PI3K

AKT

mTOR

Growth

Survival

Resistance

Genetic

Alterations

XL147

Rapalogs

47

XL147 -

Clinical

Activity

Observed

Baseline Cycle 8 –

200 mg XL147Vaginal Carcinoma

(1) Surgical resection, pelvic and periaortic

radiation, cisplatin

weekly, paclitaxel/carboplatin, and investigational therapies

54 year-old patient with vaginal cancerSequential CT scans of the abdomen

32% interval reduction of a left para-aortic soft tissue mass in Cycle 814% overall tumor reduction in Cycle 6; 21% reduction in Cycle 8

Multiple prior treatments(1)

48

XL147 –

Development

Program

Three

Phase II studies

enrolling

patientsExtensive biomarker

work

being

performed

XL147(PI3K)

Phase I

Indication Combination

AgentPhase

Ph Ib/II

Ph Ib/II

Phase II

Phase II

MTD with

expansion in NSCLCLymphoma

in MTD expansion

Endometrial, ovarian,

NSCL cancer

2nd

line endometrial

cancer

Refractory

HER2+ metastatic

Breast

cancer

Single agent

Erlotinib

Carboplatin

and paclitaxel

Single agent

Trastuzumab

orTrastuzumab/paclitaxel

Number

of Patients

125

74

35

80

74

62LetrozolePhase IIRefractory

ER/PR+ metastatic

Breast

cancer

MTD: Maximum Tolerated

Dose

NSCLC in MTD expansion

49

XL765 -

PI3K and mTOR

inhibition

Compelling mechanism of action that blocks two different enzymatic

activities along the same pathwayAs a single agent:

Strong impact on PI3K and

mTOR pathway

Effect on ERK/MAPK

pathwayDose limiting toxicity: transaminase

elevationIn combination:

Combination with temozolomide

in glioblastoma

and with erlotinib

in lung cancerDose escalation ongoing

Maximum Tolerated

Dose is

50 mg BID and 90mg QD

PI3K

AKT

mTOR

Growth

Survival

Resistance

Genetic

Alterations

XL147 XL765

Rapalogs

50

XL765 -

Demonstrates

Robust

PI3K Pathway

Inhibition

(

1

)

pEBP1T70, pPRAS40T246

and pS6S240/S244

also evaluated –

post-dose decreases of 68%, 52% and 84%, respectively; TUNEL staining

increased on average 1.6 fold. Note: This table summarizes results from all patients assessed for tumor pharmacodynamic

response. Data on file. ASCO 2010 presentation. N = 9 patients.

0

20

40

60

80

100

% In

hibi

tion

(+s.

d.)

pAKTT308 pAKTS473 pERKT202/Y204 Ki67

XL765: Average

of Percent Pathway

Inhibition(1)

“Proof of mechanism"

obtained

by demonstrating

inhibition of the PI3K pathway

in tumor

biopsies from

treated

patients

Inhibition of ERK pathway

demonstrated

51

XL765 - Development

Program

Phase I

Indication Combination

AgentPhase

Ph Ib/II

Solid

tumors

Lymphoma

in

MTD expansion

Glioblastoma

NSCLC in MTD expansion

Single agent

temozolomide

erlotinib

Number

of Patients

120

110

110

Phase II study

in ER/PR+ breast

cancer enrolling

patientsExtensive biomarker

work

being

performed

XL765 + letrozole

in refractory

ER/PR+(1)

Breast cancerletrozole 62Phase II

Ph Ib/II

(

1

)

Estrogen

Receptor

/ Progesterone

Receptor

positive

52

MM-121 -

A Novel

ERBB3 Antagonist

Importance of the ERBB3

receptorCentral signaling node in maintaining growth of tumor cellsKey regulator of AKT driven pro-

survival signals Implicated in the development of resistance to targeted and chemotherapeutic agents

Key modes of actionBlocks HEREGULIN binding to and subsequent phosphorylation

of ERBB3Inhibition of the cross talk between ERBB3 and ERBB1 or ERBB2 and consequent downstream activation of AKT

Sensitivity

Analysis

of Ligand-Induced

ERBB3 Pathway

Activation(1)

(1) Science Signaling, Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB

Receptor–PI3K Axis by Birgit Schoeberl, et al, 30 June 2009

53

MM-121 Development

Program

Translational

medicine

program to identify

biomarkers

integrated

into

clinical

trialsPhase II proof of concept program launched

in July 2010Several

other

phase II studies

to be

initiated

in the near

future

XL147(PI3K)

Phase I

Indication Combination

AgentPhase

Ph Ib/II

Phase Ib

Phase II

Solid

Tumors

NSCLC

Gynecological

tumors,

Ovarian

cancer

ER/PR+ Metastatic

breast

Single agent

Erlotinib

paclitaxel

Exemestane

Number

of Patients

55

Phase Ib: 24

Phase Ib: 24

Phase II: 240

130

54

Targeting

Key Signaling

Pathways

PI3K and HER3

Source: Drug discovery approaches targeting the PI3K/Akt pathway in cancer C

Garcia-Echeverria and W R

Sellers, Oncogene

27: 5511–5526. (1) Science Signaling, Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB

Receptor–PI3K Axis by Birgit Schoeberl, et al, 30 June 2009

ERBB family receptor tyrosine kinases, such as EGFR and HER2/neu, can be activated by mutationsERBB3 activates the PI3K pathway in response to HEREGULIN growth

factors(1)

Plans to conduct combination trials: MM-121

and XL147;

MM-121

and XL765

55

TG 101348 / SAR302503 Highly

Potent

and Selective

JAK-2 Inhibitor

Molecular characteristicsOrally available

Highly potent against wild-type and mutant JAK2 kinase

JAK2 selectivity reduces potential for off-target side effects

Myelofibrosis

disease burdenU.S. prevalence is about 14,000

Median survival is about 5 years

AML(1)

transformation is 5% to 20%

Clinical signs: enlarged spleen, bruising, bleeding, fatigue, shortness of breath, anemia

SB 1518

INCB 18424

SAR302503

CYT 387

JAK1 JAK2 JAK3 TYK2

3

2.8

22

1811

528

155

3.3

1276

428

405

Not reported

19

JAK Selectivity

Profile (2,3)

17

1002105

(1) AML: Acute Myelogenous

Leukemia(2) Measured by IC50, nM(3) Sources: SAR302503 –

Cancer Cell. 2008 April; 13:311-320; INCB 18424 -

Blood. 2010 Apr 15;115(15):3109-17; SB 1518 -

Blood 2009 November; 114: 3905; CYT 387 -

Blood. 2010 June; 115(25):5232-40

56

SAR302503 - Potentially “Best in Class”

for Myelofibrosis

Potential for “best in class”

and for myelofibrosis

disease transformationMajor spleen reduction and improvement in constitutional B symptoms(1)

Lack of spleen and cytokine rebound after missed dose or discontinuation

Signs of potential for reversal of fibrosis

Reduction in JAK2 mutant allelic burden (V617F)

Pre-treatment After

36 weeks

of SAR302503Significant Spleen Size Reduction

(1) Fever greater

than

38°

C, drenching

sweats, unintentional

weight

loss

of >10% of normal body weight

over a period

of 6 months

or less

57

SAR302503 -

Development

Program

0

10

20

30

40

50

60

70

80

Perc

enta

ge o

f Sub

ject

sCycle 1 Cycle 2 Cycle 3 Cycle 4 Cycle 5 Cycle 6

>/=50% 100%

Decrease

in Palpable Spleen Size(1)

Phase I

dose escalation

study

in MFGenerally

well

tolerated

with manageable

gastrointestinal effects, primarily

at

high

dosesManageable

anemia

observedOnce-daily

dosingIn the expansion cohort, 36/43 patients continued

on active treatment

for at

least 12 months

Phase II

in MF to start

Q1 2011

(1) ASH 2009: A Phase I Evaluation of TG101348, A Selective JAK2 Inhibitor in Myelofibrosis

–

Clinical Response is Accompanied by a Significant Reduction In JAK2V617F Allele Burden

Refractory Polycythemia

Vera

(PV)PV is driven by JAK2 mutationsPhase II

dose ranging to start 2011

58

SAR3419 –

Antibody

Drug (DM4) Conjugate

CD19 Target

Phase I -

Two dose-ranging studies in patients with refractory/relapsed B-cell lymphoma (NHL)

TED6828 (U.S.) completed; once every 3-weeks

x 6 cyclesTED6829 (France) underway; weekly

for 8 weeks

SAR3419 was

created under a research collaboration with ImmunoGen, Inc.(1) Except Multiple Myeloma

Specifically expressed on B lymphocytes

Except plasma cellsIncluding early B cell progenitors (unlike CD20)

CD19 expressed in nearly all B-cell malignancies(1)

Potentially increased cytotoxic

effect against lymphoid tumors but with lower toxicity

Drug ~

Drug ~

~ Drug

~ Drug

Monoclonal

antibody

that

binds

specifically

to an antigen

target

found

on a cancer

cell

Linker that

keeps

the

cytotoxic

agent

attached

to the

antibody

until

inside

a cancer

cell, where

it

becomes

activated

Highly

potent cytotoxic

molecule

59

Our Early

Stage Development

Portfolio: Exciting, Novel

and Embracing External Innovation

BiTE®

antibodies combine targeting cancer with activating immune cells

Potential for treating both solid and hematological cancers

Combining

targeting

capability

of a mAb

with

cytotoxic

“warhead”

Early

signs

of clinical

activity

in lymphoid

malignancies

with

SAR3419

Blocking of ErbB-family signaling through the node of highest pathway sensitivity

Anticipated favorable safety profile to facilitate combinations

XL147 is

potentially

a first-in-class PI3K inhibitor

XL765 is

first in class with

a unique mechanism

of action combining

PI3K and mTOR

inhibition

Activity with long-term tolerability in patients with myelofibrosis

Potential for best-in-class based on biochemical profile and emerging clinical data

Discovering

activators

of p53 to restore tumor

cell

sensitivity

to treatment

Novel

approach

of inhibiting

protein-

protein

interactions

60

Concluding Remarks

Debasish

Roychowdhury, MDSenior Vice President, Global Oncology Division

61

Established

a nimble

organization

Solid

portfolio after

rigorous

pipeline review

Leveraged

internal

expertise and embraced

external

innovation

Created

networks with

scientific

community

Strong

Commitment

to Success

Implementing

a new approach

to the development

of late

stage and early

stage cancer treatments

Altering

governance

structures to support innovative

work

environment

Changing

attitude

Two fast track designations

Approval and launch of Jevtana®

Improved life cycle management

Realized synergies and new efficiencies across the entire oncology division

Drawing top talent with diverse background from industry and biotech, academia

Translating research findings from academia to developing cancer drugs

Creating new models for biotech alliances

Built Delivered

Transforming Attracting

62

Q&A Session

63

Diabetes IR Thematic

Seminar

September

30, 2010

64

Sanofi-aventis Poised

for Growth in Diabetes

Pierre ChancelSenior Vice President - Diabetes Division

65

A Strong

and Experienced

Team Presenting

Today

Christoph

Heinemann

Vice President Strategy & Operations, Diabetes Division•

Director Marketing & Access, sanofi-aventis Germany

•

Director

Metabolism

Business

Units, sanofi-aventis Germany

•

Director Strategy & Business Development, sanofi-aventis Germany

Jochen

MaasVice President Research & Development, Diabetes Division• Vice President

, R&D Europe•

General Manager, R&D sanofi-aventis Deutschland GmbH

•

Professor at Gießen-Friedberg University of Applied Sciences

Pierre ChancelSenior Vice President Diabetes Division•

Senior VP Global Marketing & Access, sanofi-aventis

• Managing

Director, Aventis UK & Ireland• VP Metabolism

Worldwide, Aventis

66

Diabetes

Burden

Expected

to Increase

Dramatically

Emerging

global epidemic of diabetes

More than

285m

people worldwide

are living with diabetes

Each

year

another

7m people develop

diabetes

Diabetes

causes about 5% of all deaths

globally

each

yearDiabetes

deaths

are likely

to increase

by more than 50%

in the next

10 years

Source: WHO, Multiple sources and internal

estimates

Diabetes

Prevalence (in million patients)

201020152020

BRIC-M U.S. EUTop 5

Japan

+48%

+30% +26%+8%

260

240

220

200

160

40

20

180

% Growth

over 2010-2020

67Harris MI. Clin

Invest Med 1995;18:231–239; Nelson RG et al. Adv Nephrol

Necker Hosp 1995;24:145–156; World Health Organization 2002;Fact Sheet N°

138.

Microvascular

Complications Macrovascular

Complications

Diabetic

RetinopathyLeading

cause of blindness

in working-age

adults

Diabetic

NephropathyLeading

cause of end-stage renal

disease

Heart

DiseaseLeading

cause of mortality

in patients with

Type 2 diabetes

PeripheralVascular

DiseaseLeading

cause of non-

traumatic

lower-extremity

amputations

Diabetic

NeuropathyLeading

cause of diabetic

foot syndrome and non-traumatic

lower-extremity

amputations

Stroke25% of all ischemic

strokes

are due to diabetes

alone

or with

hypertension

Diabetes is Associated with Multiple Micro and Macrovascular

Complications

Endocrinol

Metab

Clin 1996;25:243 -

254 (DCC Trial)

Risk of complications and HbA1c

HbA1c (%)

Relative risk

in %

1

3

5

7

9

11

13

15

6 7 8 9 10 11 12

RetinopathyNephropathy

MicroalbuminuriaNeuropathy

68

Significant

Unmet

Needs

in Diabetes

U.S. and EU Countries “Treat

to Target”(1)

HbA1c –

Glycated

hemoglobin(1) Adelphi Disease Specific Program (DSP) III and VII (sample of over 10,000 diabetic patient records) (2) Multiple sources and internal estimates

BRIC-M Countries Diagnosis(2)

42

37

13

4 40

5

10

15

20

25

30

35

40

45

50

<7% 7-8% 8-9% 9-10% >10%

165

71

Diabetes Patients DiagnosedPatients

(in million patients)% of patients Recommended

HbA1c Target

(43%)

58% above

target67%

undiagnosed

69

A Rapidly

Changing

Market

1990-2000 2000-2010 2010-2020

Therapies

Treatmentapproaches

Geographies

Business models

•

Metformin

/ Sulfonylurea

•

Insulin

•

Metformin

/ Sulfonylurea

•

TZDs, GLP-1s, DPP-IVs

•

Insulin analogues / Lantus®

•

Numerous

novel

drugs

& regimens

•

New insulin

forms, low-cost

insulin

analogs

•

Disease

modifying

& regenerative

medicine

•

1 to 2 OADs

•

Late insulinization

•

Premixed insulins

•

Insulin: Specialists

•

OADs: Primary Care Physicians

•

U.S. / Europe

•

Earlier insulinization

•

More drugs in treatment algorithms

•

Disposable pens

•

Broader

role

of PCPs

•

Higher

regulatory

hurdles

•

Greater

market

access

challenges

•

Holistic

approach

to diabetes

care

•

Identification of patient subpopulations

•

Advances

in insulin

pump

therapy

•

Disease

management program offerings

to payers

•

Cost-value relationship

key

to decision

•

Growing

role

of new players

(e.g. telecom, digital media, nutrition)

•

China the future largest

diabetes

market

in the world

TZDs

–

Thiazolidinediones

GLP-1s –

Glucagon-like peptide 1 agonists DPP-IVs –

Dipeptidyl

peptidase-4 inhibitors OADS –

Oral antidiabetic

agents

•

Skyrocketing

prevalence

in Asia, Latin America

and the Middle-East

70

Diabetes

Remains

One of the Largest

Growth Opportunities

in the Healthcare

Space

One of the fastest growing marketsOutgrew pharma

market by 5 pp between 2004 and 2010 A €33bn

market projected to reach close to €50bn

by 2015

Multiple drivers for growth> 300m clinically obese people globally(3)

Aging population Sedentary lifestyleUnhealthy dietImproved screening and earlier diagnosis

(1) IMS MIDAS Q2 2010, internal

analysis

(2) Multiple sources, internal

estimates

(3) WHO, “Global Infobase”

2010 and International Obesity Task Force (IOTF)

Devices

0

10

20

30

40

50

2004 2010e * 2015e *

Global Diabetes

Market(1,2)

Insulins

& injectables

OADs

+16%

+7%

20

33

+5%

48

+11%

+4%

+7%

CAGR+9%

CAGR+8%

€bn

71

FY 2009sanofi-aventis diabetes

sales€3,764m+19.4%

Western EuropeDiabetes

sales in 2009: €858m, +6.6%Diabetes

market

share

19.4%Rank #2

22.8%

Rest

of WorldDiabetes

sales in 2009: €313m, +24.0%Diabetes

market

share

13.6%Rank #3

8.3%

Emerging

MarketsDiabetes

sales in 2009: €621m, +25.0%Diabetes

market

share

13.9%Rank #2 16.5%

Sanofi-aventis Has a Well

Established

Global Presence in Diabetes

Net sales growth is at constant exchange rate

Market share in Diabetes market: IMS MIDAS MAT June 2010W. Europe: France, Germany, UK, Italy, Spain, Greece, Cyprus, Malta, Belgium, Luxembourg, Portugal, Netherlands, Austria, Switzerland, Sweden, Ireland, Finland, Norway, Iceland, DenmarkEmerging markets: World less North America (USA, Canada), Western Europe, Japan, Australia and New ZealandRoW: Japan, Canada, Australia and New Zealand

U.S.Diabetes

sales in 2009: €1,972m, +23.8%Diabetes

market

share

17.1%Rank #2 52.4%

72

0

1

2

3

4

5

2005 2006 2007 2008 2009 H1 2010

Lantus Apidra Insuman Amaryl

: Strong

Backbone

for Sanofi-aventis

A solid

heritage

: Still

an opportunity

for entry in volume markets

: Remains

a reference

in emerging

markets

and Japan

A success

story based

on innovation

: Our flagship

brand# 1 insulin

brand worldwide

# 1 anti-diabetic

drug

worldwide(1)

: Add-on to Lantus®

in basal-bolus

regimen

Two

award-winning

pen

devices

(1) IMS MAT June

2010

Sanofi-aventis Sales in Diabetes

CAGR 16.3%

€bn

® ® ® ®

73

0

2

4

6

2007 2008 2009 2010 2011 2012 2013

Lantus Apidra Insuman Amaryl

On Track

to Deliver

on our

Ambition

x2

® ® ® ®

€bnGlobal Diabetes

Sales

74

Our Growth

Drivers over 2010-2015

BG StarTM

i-BG Star®

LixisenatideFamily

EmergingMarkets

Potential

further

change to the treatment

paradigm

of type 2 diabetes

Significant

value added

offering

beyond

glucose measurement

Competitive profile now emerging for lixisenatide

within the growing GLP-1 segment Lixisenatide/Lantus®

combination expected to offer good fasting and post-prandial

glucose control

Positioned

to offer

a full set of solutions to a fast

growing

diabetes

patient population

PipelineIn-Licensing

Covering

the full treatment

options to adress

unmet

needs

in diabetes

75

Becoming

the 360°

Partner Delivering Best-in-Class and Integrated

Diabetes

Solutions

Disease

management

Patient education

Nutrition

Oral therapies(Amaryl®, Amaryl M®)

Insulin & other injectables

(Lantus®, Apidra®, lixisenatide)

Regenerativemedicines

Disposable

(SoloSTAR®)

Reusable (ClikSTAR®)

Pump

Blood Glucose Monitoring

(BGStar®, iBGStar

TM)

76

One Global Diabetes

Division: Delivering

on Sanofi-aventis’

Ambition in Diabetes

A global organization

focused

on diabetes

leadership and innovation

Objective to become

the first global diabetes

care company

Integrated

structure

comprising

all key

functions

working

on diabetes

R&D, Device

Development, Medical

Affairs, Commercial Operations and Business DevelopmentDirect responsibility

for 12 markets

(U.S., France, Germany, UK, Italy, Spain, Brazil, Mexico, China, Russia, India

and Japan)

Headquartered

in Frankfurt

77

World-class integrated insulin- dedicated site in Frankfurt

Active ingredient production, vials and cartridges filling, pen assembly & packaging Demonstrated ability to build innovative and competitive device solutions

Fast track industrial projects in emerging markets

Local insulin manufacturer acquired in Orel, Russia in 2009Plant to manufacture Lantus®

SoloSTAR®

in Beijing, China, in 2012

Strong

In-House Manufacturing

Capabilities

78

Diabetes

R&D Pipeline Continues to Build

New human peptide for islet neogenesis

New powerful

weapon

to lowering

LDL cholesterol

and CV risk

Potential

first-in-class GPR119 receptor

agonist

acting on both

insulin

secretion

and GLP-1 release

Lixisenatide

novel once-daily GLP-1 agonist

in late phase IIICompetitive profile vs. other once-daily GLP-1 productsPromising combination with Lantus®

Devices

to become strategic priority across the portfolioBlood glucose monitoring: Partnership with

Pipeline expanding into novel classes

via external innovation

79

Building on a Strong

Commercial Presence

Christoph HeinemannVice President, Strategy & Operations - Diabetes Division

0

5

10

15

20

25

2010e * 2015e *

€bn

CAGR+11%

Sanofi-aventis Well Positioned to Sustain Growth in the Fastest Growing Diabetes Market Segment

(1) Source: IMS Data

(2) MS MIDAS Q2 2010, internal analysis

Strong Historical Performance in the Injectable

Market(1)

Share of Sales

12

21

Global Injectables

Sales Expected to Grow Double-Digit(2)

Insulins GLP-1s

0%

10%

20%

30%

40%

50%

2001 2002 2003 2004 2005 2006 2007 2008 2009

Sanofi-aventis Novo Nordisk Eli Lilly

80

81

A Portfolio of Four Marketed Brands Supporting Growth

0

1

2

3

4

2005 2006 2007 2008 20090

50

100

150

200

2005 2006 2007 2008 2009

0

50

100

150

200

2005 2006 2007 2008 2009

Net

Sal

es (€

bn)

Net

Sal

es (€

m)

Net

Sal

es (€

m)

Net

Sal

es (€

m)

0

100

200

300

400

500

600

700

2005 2006 2007 2008 2009

82

Strong

Sales Evolution across

all Geographies

Lantus®

Apidra®

Insuman®

Amaryl®

0

0,5

1

1,5

2

2005 2006 2007 2008 20090

200

400

600

800

1000

2005 2006 2007 2008 2009

0

100

200

300

400

2005 2006 2007 2008 2009

Net

Sal

es (€

bn)

Net

Sal

es (€

m)

Net

Sal

es (€

m)

Net

Sal

es (€

m)

Western Europe

Emerging

Markets Rest

of World

U.S.

0

200

400

600

800

2005 2006 2007 2008 2009

83

0

1

2

3

4

#1 Diabetes

Brand Worldwide

Worldwide Rank of Leading Diabetes Brands

MAT June 2010 (€bn)

* Includes meters and strip test products sales

Source: IMS Data and Boston Biomedical consultants

Worldwide MAT June 2010 Diabetes Products Quarterly Review (data

converted to €

using 1.3$/€)

Actos® Avandia®Novomix®Januvia®/ Janumet®

Levemir®Humalog®Novorapid®Lantus® Accu-chek®* One Touch®*

#1

84

33%33%

23%

30%

44%

37%

0%

10%

20%

30%

40%

50%

2005 2006 2007 2008 2009

Short Acting Premix Basal

Leading

the Treatment

Paradigm

Shift towards

Basal Insulin

(1) IMS Data

Global Insulin Market Share by Class(1)

66%

54%

17%

3%

17%

41%

0%

10%

20%

30%

40%

50%

60%

70%

2005 2006 2007 2008 2009

Lantus Levemir NPH

Lantus®

Owns 2/3 of the Global Basal Market(1)

®®

Market share by type of basal insulin

85

China: Strong

Growth

due to

Diabetes center of excellenceAddressing need for medical educationTrain 10,000 healthcare providers within 3 years

Significant clinical developmentORIGIN study: >450 patients from ChinaLantus®

and Amaryl®

Phase IV trialsLixisenatide: participation in GetGoal

program

Partnerships with Chinese Diabetes Society

0%

10%

20%

30%

40%

Novo N

ordisk

Bayer

sanofi

-aven

tisEli L

illy BMS

Hangzh

ou Huad

ong

Servier GSK

0%

10%

20%

30%

40%

50%

60%55%

Diabetes

Market

Share

(%) MAT Growth

vs. last year

Top 8 Companies in Diabetes(1)

(1) IMS CHPA MAT June 2010

and

86

Brazil: Diabetes Leadership for Several Years

Highly

skilled

sales force at

specialist

and GP levels

Long-term

commitments to medical

education

Full portfolio offer including

Lantus®

and Amaryl®

High level

of service to health-care system (nurses, web, point-of-care)

(1) IMS MAT June

2010

0

10

20

30

40

50

60

70

2007 2008 2009 2010

Sanofi-aventisNovo NordiskEli Lilly

Sales (€m)

Sales in the Brazilian Retail Market(1)

(1) Schreiber SA, et al. Diabetes Obes

Metab

2007;9(1):31-38

(2) Schreiber SA, et al. Diabetes Technol

Ther

2008;10(2):121-127 (3) Pfohl

M, et al. ISPOR 2008 (4) Riddle M, et al. Diabetes Care 2003:26(11):3080-3086(5) Reviewed in:Eskesen

S, et al. Fam. Pract. 2006 Nov;55(11):1001-1003

(6) Arnolds S, et al. Diabetes Care July 2010 33:1509-1515 (7) Buse

J, ADA 2010 (8) Bergenstal

RM, EASD 2010

Lantus Cornerstone in Treatment Guidelines

Adapted from D.M. Nathan et al. Diabetes Care (2009) 32 (1):193-203ADA –

American Diabetes Association EASD –

European Association for the Study of Diabetes

At diagnosis

Lifestyle+

MET

Lifestyle + MET+

Lifestyle + MET+

SU

Lifestyle intervention

+ Intensive insulinBasal Insulin

Tier 1: Well-Validated Core Therapies

Well-Established in ADA and EASD Consensus Statement

Tier 2: Less Well-Validated Core Therapies

Partner Approved

indication Studies Note

Metformin (1) –

(5)

Sulfonylurea (1) –

(5)

Glitazones Pioglitazone(5)

DPP-IVs Sitagliptin(6,7)

GLP-1sExenatide(7,8)

other studies running

--

Well-Established to Partner with Other Agents

87

88

Lantus Use Has Led to Earlier Insulinization

0%

10%

20%

30%

40%

50%

60%

1-2 years 3-4 years 5-6 years 7-8 years 9-10years

>10years

2000 2010

0%

10%

20%

30%

40%

50%

60%

1-2 years 3-4 years 5-6 years 7-8 years 9-10years

>10years

2000 2010

Type 2 diabetes

and specialists

only

Source: Adelphi

DSP

Time from

Diagnosis Time from

Diagnosis

EU U.S.Patientson insulin

Patientson insulin

89

The ORIGIN Study

Has the Potential

to Change the Landscape

of Type 2 Diabetes

Treatment

Intermediate

Hyperglycemia

an important predictor

of diabetes

and CV risk2-fold

increased

risk

of diabetes

when

both

IFG and IGT are present(1)

IGT a marker for both

increased

risk

for diabetes

and CV disease(1)

More than

4 m people with

early

diabetes

in the U.S. and top 5 EU countries(2)

Other agents for glycemic

control

Endpoints:CV morbidity/mortality

All-cause mortality

Risk of diabetic microvascular

outcomes

Rate of progression of IFG or IGT to type 2 diabetes

+/-

ω-3 PUFA

+/-

ω-3 PUFA

Patients at

high

CV riskand IFG, IGT or newly

detected

diabetes

or established

diabetes(on 0 or 1 oral agent)

(1) Metabolic Disorders Study, Decision Resources, 2010 (2) GfK

2008 & Roper Global Diabetes Report. (Early diabetes: Type 2 diabetes patients with CV risk and on diet & exercise or 1 OADORIGIN: Rationale, design, and baseline characteristics in Gerstein HC, et al. Am Heart J 2008;155:26–32PUFA –

Polyunsaturated fatty acids IFG–

Impaired fasting glucose IGT–

Impaired glucose tolerance

90

Strong

and Sustainable

Platform for the Future

Insulin analogues are biological productsBiotechnology-derived proteins

Lantus®

covered by compound patent in key countries until November 2014

6-month pediatric exclusivity granted in the U.S. until February 2015 (pediatric study underway in EU)

No specific regulatory pathway currently established

U.S.: Under considerationEU: Guidance only for biosimilar

human soluble insulin since June 2006

Production capacity to meet market demand an important factor

Continuous COGS improvementLife-cycle management

Patient Support

Lantus®

to Become

Part of an Integrated

offer

MedicalEducation

91

Blood Glucose Monitoring Market is a Highly Attractive Market

Strip usage%

65%

23%

11%

1%

Strip Usage Pyramid

PumpUsers

IntensiveInsulin Users

OAD Users ± GLP-1

Diet & Exercise (No drugs)

Conventional Insulin + Basal

More Than 80% of Strips are Used by Insulin Patients(1)

(1) Proprietary Market Research(2) Source: Sanofi-aventis analysis using data from Boston Biomedical consultantsWorldwide Q1:10 Diabetes Products Quarterly ReviewSales 2010-2015=$69,248bn data converted to € using 1.3€/$

6.66.8

5.75.04.7

10.8

7.4

0

2

4

6

8

10

12

2005

2006

2007

2008

2009

2010

E20

11E

2012

E20

13E

2014

E20

15E

BGM Market Sales Forecasts

€bnCAGR (2005-2015e):

8 %

Market Offers Sustainable Growth(2)

No Generics

92

Co-Development

of innovative Devices

& Strips

Supply

viaCommercialization

through

sanofi-aventis

Strong

Partnership

with

Co-exclusive access to patented Dynamic ElectrochemistryTM

New levels of accuracy translating into higher patient safetyNo-coding, fully compliant with FDA requirements (no GDH-PQQ )

GDH-PQQ –

Gglucose

dehydrogenase

pyrroloquinoline

quinoneSource: AgaMatrix

(1) Parkes, J.L., et al Diabetes Care; 23:1143-1148, 2000.

Consenus

Error Grid

00 600500400300200100

600

500

400

300

200

100

iBGStarTM

Meter (mg/dL)

100% iBGStarTM in highest accuracy area(1)

Reference: YSI 2300 (mg/dL)

93

Leading

Innovation Towards Mobile Diabetes

Management

• First meter to connect to iPhone

and iPod touch

• Easy-to-use, no-coding

• Discreet design

• Applications to support Disease Management

CE mark and 510 k submission planned in Q4 2010 for iBGStarTM

94

Smartphone Platform Providing Superior Applications for Patient Self-management

Distribution of Smartphone Users Among

Diabetes

Population (U.S. estimates)

Smart phone usage of diabetic

patients increasing

from

17% today

to 46% in 2014

•

Electronic logbook for blood glucose, insulin dose and carbohydrates

•

Color-coding for hypo-hyperglycaemia

•

Seamless data exchange & communication

CE mark and 510 k submission planned in Q4 2010 for iBGStarTM

4.13.32.61.91.3

6.55.3

4.13.1

2.1

3.1

2.6

2.0

1.51.1

0

2

4

6

8

10

12

14

2010 2011 2012 2013 2014

65+45-6420-44

million

Sources: AdMob

Mobile Metrics Highlights May 2010, Gartner Mobile Trends 2010,

International Diabetes Federation website

95

Meal-time tagging

for glucose patterns

Positive feedback

Meal-time tagging

for glucose patterns

Positive feedback

Patented

Dynamic

Electrochemistry®

for assured

accuracy

Integrated Support Services 24h / 7d for Insulins, SoloSTAR®

/ ClikSTAR®

and iBGStarTM

Mini-USB for data transfer

to PC

Mini-USB for data transfer

to PC

Easy-to-use meterNo coding

Large, backlit

display

Easy-to-use meterNo coding

Large, backlit

display

Designed

by Listening

to Patients

96

Advanced technology:

Expertise with pen devices

Strong commercial presencePhysicians, nurses, pharmacies

Business model leveraging synergiesDiabetes sales forces for HCPsDTC for patientsDistribution: Wholesalers, pharmacy and mail-orderCustomer service integrating Lantus®

Revenues on sales of stripsPositive halo effect expected on Lantus®

and other products

All Elements

in Place for Successful

BGM Market

Entry

Launches

in U.S., Germany and France early

Q1 2011

Further

roll-out across

Europe in 2011Asia

and Latin America

launches

planned

for 2012

CE mark and 510K obtained for BGStar®

CE mark and 510 k submission planned in Q4 2010 for iBGStarTM

97

BGStar®

and iBGStarTM: Introductory video

98

Today’s

Commitments for the Treatments

of Tomorrow

Jochen

MaasVice President, Research & Development - Diabetes Division

99

Holistic

Approach

to Innovation in Diabetes

Diabetes

Pre-Diabetes

and Diabetes

are the “entry”

into

multiple diseases

Innovative Improvement of the Classical Paradigm• New drug combinations• New modes of action• New insulins

+ Risk

Factors• Lipid

disorders• Obesity• Metabolic

syndrome

+ Late Manifestations• Microvascular

complications• Macrovascular

complications

+ Diagnosis

and Devices• Monitoring• Delivery

(pen

devices, pumps)

100

Diversity

of Targets

to Address

Unmet

Needs

in Diabetes

–

Five Main Pillars

for R&D

Short-Mid

Term

Win

Improve

on classical

paradigm

•

Extended drug action•

Combinations•

Improved devices•

Safer compounds•

Disruptive device

technology

•

New superior insulins•

Cost-effective solutions

Long-Term

Win

Address

-celldefect

Protectend-organs

•

Protect/improve

-

cell

function•

Preserve/increase

-

cell

mass•

Replace -cell

pool via regeneration,

cell

or gene

therapy

•

Microvascular

complications:

NephropathyNeuropathyLimb ischemiaRetinopathyWound healing•

Macrovascular

complications:

CAD / MIStroke

Less

Morbidity, Better

Quality

of Life, “More Value for Money”

Towards

artificialpancreas

Development of closed-loop system•Continuous glucose sensors•Insulin pumps, IT and control algorithm•Short-acting insulins

and glucagon analogues

Correct metabolic

dysfunction

•

Mimic caloric restriction

•

Target mitochondria dysfunction

•

Address lipid dysfunction (lipid toxicity, dyslipidemia, NAFLD/NASH)

•

Address vascular and cardiomuscular

metabolism dysfunction

Clinicians Patients PayersHealth

Care Providers

NAFLD –

Non-Alcoholic Fatty Liver Disease

NASH –

Non-Alcoholic Steato

Hepatitis

101

Worldwide

Connected

Network of Selected

Partners

EUROPE

Corporate Partners•

Genfit, France•

Zealand Pharma, Denmark

Academia/Consortia•

AVIESAN (Alliance Nationale

pour les Sciences de la Vie et de la Santé), France

•

IMI (Innovative Medicines Initiative) / IMIDIA (Innovative Medicines Initiative Diabetes project), EU

•

Institut

de la Vision, France•

Charité

-

Universitätsmedizin

Berlin, Germany•

Juvenile Diabetes Research Foundation (JDRF), WW

Academia•

California

Institute of Technology•

Salk

Institute for Biological

Studies•

Burnham Institute

Corporate Partners•

AgaMatrix•

CureDM•

Regeneron•

Wellstat•

Metabolex

U.S. ASIA

Corporate Partners•

Huya, China

Academia•

SIBS (Shanghai Institutes for Biological

Sciences), China

102

Lantus®

Insulin glargine

Reduction in CV morbidity & mortality

SAR236553 (REGN727)

Anti-PCSK9 mAb

Hypercholesterolemia

SAR260093 (MBX-2982)

GPR-119 agonist

Type 2 Diabetes

lixisenatide

+ Lantus®

GLP-1 agonist + insulin glargine

Type 2 diabetes

SAR176975 (PN2034)

Insulin

sensitizer

Type 2 diabetes

lixisenatide

(AVE0010)

GLP-1 agonist

Type 2 diabetes

Phase I

Phase II

Phase III

Pipeline Products

in Development

Already

a Significant

Expansion of the Diabetes R&D Portfolio

Status

Update

Phase IIa

study results expected in Q4 2010

Planned

submissions

for EU and Japan

in H2 2011 and for the U.S. in H2 2012

Investigated

as “free combination”

in Phase III

Evaluating

preclinical

observations and performing

additional

preclinical

work

ORIGIN study

results

expected

in 2012

Initiation of Phase II expected

in H1 2011

Partners: Lixisenatide

(AVE0010)/Zealand Pharma

–

SAR176975 (PN2034)/Wellstat Therapeutics –

SAR260093 (MBX-2982 )/Metabolex

–

SAR236553 (REGN727)/Regeneron

103

Lixisenatide: A New GLP-1 to Overcome

Limitations of Standard Type 2 Diabetes

Treatments

Current

Therapy

Limitations•

Risk

of hypoglycemia

•

Inadequate

PPG control•

Weight

gain

•

Specific

adverse events•

Progressive ß-cell

failure

GLP-1 Actions•

Low

risk

of hypoglycemia

•

Pronounced

effect

on PPG•

Weight

loss

•

Good safety

profile•

ß-cell

preservation

effect

(animal models)

Lixisenatide•

Modified

exendin-4 molecule

•

SIP®

technology•

Half

life ideal

for once daily

dosing

PPG –

Post-Prandial

Plasma Glucose

104

Lixisenatide: Promising Profile in Phase IIb

Good effect on HbA1c, postprandial glucose levels and weight loss

Favorable gastrointestinal tolerability profile (nausea, vomiting or diarrhea)

Convenient once-daily subcutaneous injection

Clear dose-effect relationship 20 μg

once-daily selected for

phase III

Ratner

R, Poster 433P, ADA 2008 13-week, multicenter, randomized, placebo-controlled, parallel-group study in metformin-treated patients (52-56 patients/group) –

Results of 5, 10, 20, 30μg BID not given in above charts

HbA1c (%)

-0.8

-0.6

-0.4

-0.2

0

AVE0010 QD Dose

Cha

nge

in H

bA1c

at

Wee

k13

5

μg placebo

10μg

20

μg

30μg

(Baseline mean

HbA1c: 7.55%)

Mean

Body Weight

(kg)

-4

-3

-2

-1

0

AVE0010 QD DoseCha

nge

in W

eigh

tat

Wee

k13

placebo5

μg

10μg

20

μg

30μg

(Baseline mean

weight: 89kg)

105

Phase III Program Covers Multiple Treatment

Paradigms

Study Objective # of Patients

GETGOAL-MONOMonotherapy

360

GETGOAL-MDose flexibility

680

GETGOAL-F1Titration

regimen

(1 or 2-step

titration) 450

GETGOAL-SEfficacy

on top of SU (+

MET)855

GETGOAL-PEfficacy on top of pioglitazone

(+

MET)450

GETGOAL-X Head-to head vs. exenatide

(+

MET) 600

GETGOAL-LEfficacy

on top of basal insulin(+

MET)450

GETGOAL-L

Asia

Efficacy

on top of basal insulin(+

SU)300

GETGOAL-MONO Japan

Monotherapy 66

GETGOAL-M-AsChina

Efficacy

on top of MET (+

SU) 380

Program fully enrolled(1)

All studies expected to be completed and analyzed in 2010 or 2011 Lixisenatide

given 20 µg

once-daily for 24 weeks(2)

Long-term study extensions includedFirst results available for

GETGOAL-MONOGETGOAL-L Asia

Phase II/IIIb

studies initiatedVs. liraglutideVs. sitagliptin

(1) Except GETGOAL-M-As which started mid-2010 (2) Except in GETGOAL-MONO (12 weeks) SU –

Sulfonylurea MET –

Metformin

106

GETGOAL-MONO: Encouraging

Initial Phase III Data

Statistically significant improvement in all blood glucose parameters

Pronounced effect on PPG

More patients reached HbA1c targets in lixisenatide

groups

Mean decrease in body weight (-2 kg) observed in all study groupsGood safety and tolerability

Gastro-intestinal adverse eventsNausea: 22.2% (lixi.) vs. 4.1% (placebo)

Vomiting: 7.1% vs. 0%

Diarrhoea: 2.9% vs. 2.5%

FPG -

Fasting Plasma Glucose PPG –

Post-Prandial

Plasma GlucoseGETGOAL-MONO: 12-week study in patients with type 2 diabetes not treated with antidiabetic

agents (361 patients randomized)Baseline overall mean HbA1c 8.04 % Baseline overall mean body weight 87.2 kg

Efficacy Parameters

Two-Step Titration

One-Step Titration

Change in HbA1c (%) vs. placebo

-0.54 -0.66

Change in FPG (mmol/L) vs. placebo

-0.87 -1.08

Change in 2-hour PPG (mmol/L) vs. placebo

-3.86 -4.82

% of patients with HbA1c 6.5%

31.9 25.4

(12.5% in placebo group)

% of patients with HbA1c <7%

52.5 46.5

(26.8% in placebo group)

GETGOAL-L Asia Shows First Results of Lixisenatide Used on Top of Basal Insulins

Lixisenatide

given as add-on treatment to basal insulin ±

SU

60% of patients on Lantus®

Study met HbA1c

primary endpointNo specific safety concernFull data presentation expected in 2011 at ADASimilar GETGOAL-L trial in U.S., EU & other countries

GETGOAL-L Asia: 24-week study in patients with Type 2 diabetes previously treated with basal insulin ± sulfonylurea (311 patients randomized)Baseline mean HbA1c: lixisenatide

8.54% Placebo 8.52%

Mean Change in HbA1c Baseline to Endpoint

0.11

-0,77

LS Mean Change vs. Placebo -0.88-1

-0,8

-0,6

-0,4

-0,2

0

0,2

Plac

ebo

N=1

54

Lixi

sena

tide

N=1

46

p<0.0001

107

108

Lixisenatide, Emerging Competitive Profile in the GLP-1 Arena

Current trial results bode well for the success in demonstrating an excellent profile The right candidate after OAD failure or as an add-on to basal insulinsPen device planned for market entryCardiovascular investigational plan aiming at making lixisenatide

the first GLP-1 with a cardio-safety “claim”

at launch (U.S.)

Cardiovascular outcome study initiated mid-2010

6,000 patients with Type 2 Diabetes who experienced an Acute Coronary Syndrome event

Full Range of Delivery Systems Considered

109

Lixisenatide: the 1st

Step to a Unique Combination with Lantus®

Elements in favor of a GLP-1 acting on PPG vs. short-acting or premix insulins

Better weight managementLower risk of hypoglycemiaLimited number of daily injections

Strong rationale for combination with Lantus®

Lantus®

the only true 24h basal insulinMixability

of compoundsLixisenatide

successfully tested on top of Lantus®

in GETGOAL-L AsiaComplete Phase III development plan being finalized following interactions with FDA / EMA

Expected Benefits on Fasting and Post-Prandial

Glucose

Blood glucose

PPG –

Post-Prandial

Plasma Glucose

Breakfast Lunch Dinner

Blood glucose

110

Different Patient Populations Likely to Benefit from lixisenatide

and Lantus®

Combined Use

Patients who have failed on OADsEarly stage patients failing 1 or 2 OADs

(HbA1c>8.0%) and overweight or obese (BMI>30)

GLP-1 optimizationPatients already

treated

with

a GLP-1 and still

uncontrolled

(HbA1c>7.5%)

Lantus®

optimizationPatients already on Lantus®

who could benefit from a GLP-1 induced additional post-prandial

effectCurrently investigated in clinical trial(2)

~5m patients

~1.8m patients

~2.2m patients

Estimated

Target Population(1)

(U.S. and top 5 EU countries)

(1) Adelphi

estimates

(2) Study

EFC10781

111

: Continuous

Commitment

to Safety

Any

new observational

study

on the associations between

insulin

and cancer risk

needs

to be

of the highest

standards

Consensus on Best Practices published

in December

2009(1)

Ambitious

epidemiological

investigational

plan ongoing:

Two

retrospective

cohort

studiesPrescription databases

in Nordic

countriesU.S. diabetes

registriesData presentation

expected

in 2012

One case-control study

The International Study on Insulin and Cancer (ISAC)A case-control study

of recent

breast

cancer occurring

in patients with

diabetes

selected

from

general

practiceFrance, UK and CanadaData presentation

expected

in 2013

(

1

)

P Boyle, ecancer, 174, 11/12/2009

112

Targeting

Slowdown

of Diabetes

Progression with

a Novel

GPR Agonist

SAR260093: A potent selective orally active GPR119 agonist

Unique dual mechanism of action (insulin secretion and GLP-1 release)

Phase IIa

results expected in Q4 2010

GPR –

G-protein-coupled

receptors

Figure sourced from Overton, HA et al.; Br. J. Pharmacol. 2008, 153, S76-S81.

113

LDL levels

Corrections of Metabolic

Dysfunctions Lower

PCKS9 Leads

to Lower

LDL and CV Risk(1)

PCSK9

LDLR degradation

LDL

LDLR

(1) Cohen J, et al. N Engl

J Med 2006; 354:1264-1272c

Inhibition of the PCSK9 enzyme

# of Low

Density Lipoprotein

Receptors

(LDLR)

114

Encouraging Early Phase I Data: Read Out with our Anti-PCSK9 mAb

> 60% LDL reduction following single iv doseSimilar LDL reduction with single dose delivered scDuration of effect with sc dosing suggests at least q2week dosing, if not moreNo serious adverse events to datePreliminary data suggest similar magnitude of LDL reduction when added to statins

in Familial

Hypercholesterolemia (FH) and non-FH subjectsInitiation of Phase II program expected in H1 2011

-70%

-60%

-50%

-40%

-30%

-20%

-10%

0%0 1 3 7 10 14

Days

% C

hang

e in

LD

L fro

m B

asel

ine

Dose G Dose H Dose I

SAR236553

Single Dose sc

Effect

on LDL

SC–

Sub-cutaneous

115

One of the First Regenerative

Approaches

Entering

into Clinical

Trials

Pancreatic islet neogenesis, one of the potential curative approaches to restore patients own pancreatic functionSAR288233, the Human proIslet

Peptide (HIP)(1)

14-amino acid bioactive peptideImproved glycemic

control and significant increased islet number observed in mice(2)

Could apply to both type 1 and type 2 patients Ready to enter Phase I in 2011

Light green: Adult

pancreatic

isletcontaining

ß-cells

which

still

proliferate

(1) Partnership with CureDM(2) Levetan

C et al. Endocr

Pract. 2008;14(No. 9);1075-1083

116

Early

Projects

Directly

Addressing

Complications of Diabetes

Cardiovascular complicationsStrong effectiveness evidenced with Cathepsin

A inhibitor SAR164653 in pharmacological models of heart

failureInnovative first-in-class approach

Very favorable ADME and safety profile demonstrated in preclinical studies

Phase I expected to start in 2011

Diabetic nephropathy

SAR101099,

a long lasting

Urotensin

II antagonistPhase I initiated in Q3 2010

Intensive cooperation with internal partners (e.g. Fovea, Fibrosis Unit)

(1) AHA heart

disease

statistics

2010

(2) http://schoolwalk.diabetes.org

Increased

Risk

of Serious Complications in

Diabetes(1,2)

2-fold

increase

in the risk

of death

within

one year

post-MI

Diabetes, the leading

cause of kidney

failure

Diabetic

retinopathy, a leading

cause of blindness

117

Concluding

Remarks

Pierre ChancelSenior Vice President - Diabetes Division

118

Sanofi-aventis –

Poised

for Growth

in Diabetes

Diabetes presents healthcare and economic challenges in terms of prevention and control

Diabetes is one of the largest business opportunities in the healthcare space and a growth platform for sanofi-aventis

Sanofi-aventis is well positioned with concrete steps forward fulfilling our vision to deliver tailored and integrated solutions to people living with diabetes and healthcare providers

Lantus®

poised for future growth despite a more complex environmentLixisenatide

and [lixisenatide

+ Lantus®] opportunity to open new avenues in the management of diabetesR&D and business development fully committed to adress

unmet needs Towards an integrated offer with new devices

119

Q&A Session

120

Conclusion

Hanspeter

SpekPresident, Global Operations